Researchers at the Stanford University School of Medicine have discovered that when a certain aggressive leukaemia is causing havoc in the body, the solution may be to force the cancer cells to grow up and behave.

After a chance observation in the lab, the researchers found a method that can cause dangerous leukaemia cells to mature into harmless immune cells known as macrophages.

The findings are described in a paper that published online March 16 in the Proceedings of the National Academy of Sciences.

B-cell acute lymphoblastic leukaemia with a mutation called the Philadelphia chromosome is a particularly aggressive cancer with poor outcomes, said Ravi Majeti, MD, PhD, an assistant professor of medicine and senior author of the paper.

So finding potential treatments is particularly exciting.

Majeti and his colleagues made the key observation after collecting leukaemia cells from a patient and trying to keep the cells alive in a culture plate.

“We were throwing everything at them to help them survive,” said Majeti, who is also a member of the Stanford Cancer Institute and the Stanford Institute for Stem Cell Biology and Regenerative Medicine.

An unusual metamorphosis

Postdoctoral scholar Scott McClellan MD, PhD, a lead author of the paper, mentioned that some of the cancer cells in culture were changing shape and size into what looked like macrophages.

Majeti concurred with that observation, but the reasons for the changed cells were a mystery until he remembered an old research paper, which showed that early B-cell mouse progenitor cells could be forced to become macrophages when exposed to certain transcription factors — proteins that bind to certain DNA sequences.

“B-cell leukaemia cells are in many ways progenitor cells that are forced to stay in an immature state,” Majeti said.

So McClellan and student Christopher Dove, an MD/PhD student and the paper’s other lead author, did more experiments and confirmed that methods shown to have altered the fate of the mouse progenitor cells years ago could be used to transform these human cancer cells into macrophages, which can engulf and digest cancer cells and pathogens.

Majeti and his colleagues have some reason to hope that when the cancer cells become macrophages they will not only be neutralised, but may actually assist in fighting the cancer.

Like a bloodhound owner who gives the dog a sniff of an object that was associated with the person or animal he wants to track, macrophage cells present recognisable bits of abnormal cells to other immune cells so that they can launch an attack.

“Because the macrophage cells came from the cancer cells, they will already carry with them the chemical signals that will identify the cancer cells, making an immune attack against the cancer more likely,” Majeti said.

The hope for a therapy

The researchers’ next steps will be to see if they can find a drug that will prompt the same reaction and that could serve as the basis for a therapy for the leukaemia.

There is some precedent for such a treatment.

Retinoic acid is commonly used to treat another cancer called acute promyelocytic leukaemia.

In that case, retinoic acid is used to turn cancer cells into mature cells called granulocytes.

This treatment is the only well-established therapy that matures, or “differentiates,” cancer cells, but researchers around the world are hopeful of finding many more.

“There’s big-time interest in differentiation therapies for cancer,” Majeti said.

Source: Stanford Medicine